Global equity funds attracted net inflows for the first time in four weeks in the week through June 11, driven by a benign ...

That's because the team at Bell Potter believes it has the potential to rise almost 50% from current levels. Get the latest ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

During Q1 2025, the Harbor Long-Short Equity ETF returned 5.23% (NAV), outperforming its benchmark, the HRFX Equity Hedge ...

In a report released today, Joel Beatty from Robert W. Baird maintained a Buy rating on Axsome Therapeutics ( AXSM – Research Report ), with a price target of $157.00. The company’s shares opened ...

US Court of Appeals upholds Acadia Pharmaceuticals' patent for Nuplazid, securing protection against generic competition ...

Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the U.S. Court of Appeals has upheld the validity of its patent for ...

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...